{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Changes to the Purple Book:  Progress in Transparency",
    "url": "https://www.lexblog.com/2021/08/02/changes-to-the-purple-book-progress-in-transparency/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-JMYYR43P",
        "url": "https://www.lexblog.com/lib/JMYYR43P/"
    },
    "datePublished": "2021-08-02T13:44:10-04:00",
    "dateModified": "2021-08-02T10:44:21-04:00",
    "author": {
        "@type": "Person",
        "name": "Andrew J. Storaska"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Rothwell Figg"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Biosimilars Law Bulletin",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.biosimilarsip.com/?p=5486",
    "sourceStability": "may-move"
}